OrthoPediatrics projects $265M-$269M 2026 revenue and reiterates ~$25M adjusted EBITDA as it targets 2026 free cash flow break-even (NASDAQ:KIDS)
· seekingalpha.com
OrthoPediatrics (KIDS) Q2 2026 earnings call highlights: 15% revenue growth, record EBITDA, raised guidance, and 2H26 free cash flow outlook—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...